List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3721554/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Small Vessel Disease Progression on Long-term Cognitive and Functional Changes After Stroke. Neurology, 2022, 98, .	1.1	9
2	Prevalence and Significance of the Vessel-Cluster Sign on Susceptibility-Weighted Imaging in Patients With Severe Small Vessel Disease. Neurology, 2022, 99, .	1.1	11
3	Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. European Stroke Journal, 2021, 6, 81-88.	5.5	17
4	Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis. Lancet Psychiatry,the, 2021, 8, 225-236.	7.4	77
5	Rates, risks and routes to reduce vascular dementia (R4vad), a UK-wide multicentre prospective observational cohort study of cognition after stroke: Protocol. European Stroke Journal, 2021, 6, 89-101.	5.5	15
6	Selective Motion Artefact Reduction via Radiomics and k-space Reconstruction for Improving Perivascular Space Quantification in Brain Magnetic Resonance Imaging. Lecture Notes in Computer Science, 2021, , 151-164.	1.3	1
7	Predicting specific abilities after disabling stroke: Development and validation of prognostic models. International Journal of Stroke, 2021, 16, 935-943.	5.9	3
8	Sources of systematic error in DCEâ€MRI estimation of Iowâ€level bloodâ€brain barrier leakage. Magnetic Resonance in Medicine, 2021, 86, 1888-1903.	3.0	21
9	ESO Guideline on covert cerebral small vessel disease. European Stroke Journal, 2021, 6, CXI-CLXII.	5.5	68
10	Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage. JAMA Neurology, 2021, 78, 1179.	9.0	25
11	Relationship between inferior frontal sulcal hyperintensities on brain MRI, ageing and cerebral small vessel disease. Neurobiology of Aging, 2021, 106, 130-138.	3.1	5
12	Small vessel disease is associated with altered cerebrovascular pulsatility but not resting cerebral blood flow. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 85-99.	4.3	77
13	Predictors of Lesion Cavitation After Recent Small Subcortical Stroke. Translational Stroke Research, 2020, 11, 402-411.	4.2	12
14	Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease. European Stroke Journal, 2020, 5, 297-308.	5.5	22
15	Reporting "specific abilities―after major stroke to better describe prognosis. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104993.	1.6	4
16	Cilostazol for Secondary Prevention of Stroke and Cognitive Decline. Stroke, 2020, 51, 2374-2385.	2.0	68
17	Perivascular spaces in the brain: anatomy, physiology and pathology. Nature Reviews Neurology, 2020, 16, 137-153.	10.1	405
18	Relationship Between Venules and Perivascular Spaces in Sporadic Small Vessel Diseases. Stroke, 2020, 51, 1503-1506.	2.0	20

#	Article	IF	CITATIONS
19	A Framework for Jointly Assessing and Reducing Imaging Artefacts Automatically Using Texture Analysis and Total Variation Optimisation for Improving Perivascular Spaces Quantification in Brain Magnetic Resonance Imaging. Communications in Computer and Information Science, 2020, , 171-183.	0.5	4
20	Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial. Frontiers in Neurology, 2019, 10, 723.	2.4	9
21	Maintaining hope after a disabling stroke: A longitudinal qualitative study of patients' experiences, views, information needs and approaches towards making treatment decisions. PLoS ONE, 2019, 14, e0222500.	2.5	22
22	Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet, The, 2019, 393, 2613-2623.	13.7	134
23	Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurology, The, 2019, 18, 643-652.	10.2	68
24	Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. EClinicalMedicine, 2019, 11, 34-43.	7.1	36
25	Clinical diagnosis of TIA or minor stroke and prognosis in patients with neurological symptoms: A rapid access clinic cohort. PLoS ONE, 2019, 14, e0210452.	2.5	7
26	The impact of early-life intelligence quotient on post stroke cognitive impairment. European Stroke Journal, 2018, 3, 145-156.	5.5	31
27	The effect of different combinations of vascular, dependency and cognitive endpoints on the sample size required to detect a treatment effect in trials of treatments to improve outcome after lacunar and non-lacunar ischaemic stroke. European Stroke Journal, 2018, 3, 66-73.	5.5	10
28	Cerebrovascular reactivity measurement in cerebral small vessel disease: Rationale and reproducibility of a protocol for MRI acquisition and image processing. International Journal of Stroke, 2018, 13, 195-206.	5.9	47
29	Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination. International Journal of Stroke. 2018, 13, 530-538.	5.9	22
30	STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 11-23.	2.4	41
31	Interhemispheric characterization of small vessel disease imaging markers after subcortical infarct. Brain and Behavior, 2017, 7, e00595.	2.2	8
32	Retinal microvascular network geometry and cognitive abilities in community-dwelling older people: The Lothian Birth Cohort 1936 study. British Journal of Ophthalmology, 2017, 101, 993-998.	3.9	25
33	Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2017, 48, e44-e71.	2.0	284
34	Small Vessel Disease and Dietary Salt Intake: Cross-Sectional Study and Systematic Review. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 3020-3028.	1.6	29
35	Optimizing the Definitions of Stroke, Transient Ischemic Attack, and Infarction for Research and Application in Clinical Practice. Frontiers in Neurology, 2017, 8, 537.	2.4	51
36	Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1319-1337.	4.3	80

#	Article	IF	CITATIONS
37	On the computational assessment of white matter hyperintensity progression: difficulties in method selection and bias field correction performance on images with significant white matter pathology. Neuroradiology, 2016, 58, 475-485.	2.2	9
38	METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimer's and Dementia, 2016, 12, 1235-1249.	0.8	82
39	Endothelial Function, Inflammation, Thrombosis, and Basal Ganglia Perivascular Spaces in Patients with Stroke. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2925-2931.	1.6	28
40	Development and initial evaluation of a semi-automatic approach to assess perivascular spaces on conventional magnetic resonance images. Journal of Neuroscience Methods, 2016, 257, 34-44.	2.5	43
41	Magnetic resonance imaging for assessment of cerebrovascular reactivity in cerebral small vessel disease: A systematic review. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 833-841.	4.3	61
42	Early life characteristics and late life burden of cerebral small vessel disease in the Lothian Birth Cohort 1936. Aging, 2016, 8, 2039-2061.	3.1	20
43	A Comparison of Location of Acute Symptomatic vs. â€~Silent' Small Vessel Lesions. International Journal of Stroke, 2015, 10, 1044-1050.	5.9	59
44	Suitability of UK Biobank Retinal Images for Automatic Analysis of Morphometric Properties of the Vasculature. PLoS ONE, 2015, 10, e0127914.	2.5	56
45	Enlarged Perivascular Spaces and Cerebral Small Vessel Disease. International Journal of Stroke, 2015, 10, 376-381.	5.9	219
46	Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome. Stroke, 2015, 46, 361-368.	2.0	142
47	Clinically Confirmed Stroke With Negative Diffusion-Weighted Imaging Magnetic Resonance Imaging. Stroke, 2015, 46, 3142-3148.	2.0	104
48	Plasma Biomarkers of Inflammation, Endothelial Function and Hemostasis in Cerebral Small Vessel Disease. Cerebrovascular Diseases, 2015, 40, 157-164.	1.7	40
49	Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis. Cerebrovascular Diseases, 2014, 37, 64-75.	1.7	134
50	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurology, The, 2013, 12, 822-838.	10.2	3,919
51	Variation in Risk Factors for Recent Small Subcortical Infarcts With Infarct Size, Shape, and Location. Stroke, 2013, 44, 3000-3006.	2.0	62
52	How Much Do Focal Infarcts Distort White Matter Lesions and Global Cerebral Atrophy Measures?. Cerebrovascular Diseases, 2012, 34, 336-342.	1.7	29
53	Lack of Association of White Matter Lesions with Ipsilateral Carotid Artery Stenosis. Cerebrovascular Diseases, 2012, 33, 378-384.	1.7	59
54	Determining the Modified Rankin Score After Stroke by Postal and Telephone Questionnaires. Stroke, 2012, 43, 851-853.	2.0	52

#	Article	IF	CITATIONS
55	Visual Neglect Following Stroke: Current Concepts and Future Focus. Survey of Ophthalmology, 2011, 56, 114-134.	4.0	74
56	Use of dynamic contrast-enhanced MRI to measure subtle blood–brain barrier abnormalities. Magnetic Resonance Imaging, 2011, 29, 305-314.	1.8	61
57	Little Association between Intracranial Arterial Stenosis and Lacunar Stroke. Cerebrovascular Diseases, 2011, 31, 12-18.	1.7	37
58	Characteristics of patients with minor ischaemic strokes and negative MRI: a cross-sectional study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 540-542.	1.9	62
59	Retinal Arteriolar Geometry is Associated with Cerebral White Matter Hyperintensities on Magnetic Resonance Imaging. International Journal of Stroke, 2010, 5, 434-439.	5.9	33
60	Associations of Clinical Stroke Misclassification (†̃Clinical-Imaging Dissociation') in Acute Ischemic Stroke. Cerebrovascular Diseases, 2010, 29, 395-402.	1.7	58
61	Counting Cavitating Lacunes Underestimates the Burden of Lacunar Infarction. Stroke, 2010, 41, 267-272.	2.0	101
62	A Systematic Review of Dynamic Cerebral and Peripheral Endothelial Function in Lacunar Stroke Versus Controls. Stroke, 2010, 41, e434-42.	2.0	103
63	Enlarged Perivascular Spaces on MRI Are a Feature of Cerebral Small Vessel Disease. Stroke, 2010, 41, 450-454.	2.0	637
64	Retinopathy in Ischemic Stroke Subtypes. Stroke, 2009, 40, 389-393.	2.0	14
65	Improving Interrater Agreement About Brain Microbleeds. Stroke, 2009, 40, 94-99.	2.0	302
66	Lacunar stroke is associated with diffuse blood–brain barrier dysfunction. Annals of Neurology, 2009, 65, 194-202.	5.3	295
67	Changes in Background Blood–Brain Barrier Integrity Between Lacunar and Cortical Ischemic Stroke Subtypes. Stroke, 2008, 39, 1327-1332.	2.0	75